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BACKGROUND
Chronic lymphocytic leukemia (CLL) primarily affects older persons who often 
have coexisting conditions in addition to disease-related immunosuppression and 
myelosuppression. We conducted an international, open-label, randomized phase 
3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously un-
treated older patients with CLL or small lymphocytic lymphoma.
METHODS
We randomly assigned 269 previously untreated patients who were 65 years of age 
or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlo-
rambucil. The primary end point was progression-free survival as assessed by an 
independent review committee.
RESULTS
The median age of the patients was 73 years. During a median follow-up period of 
18.4 months, ibrutinib resulted in significantly longer progression-free survival than 
did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression 
or death that was 84% lower with ibrutinib than that with chlorambucil (hazard 
ratio, 0.16; P<0.001). Ibrutinib significantly prolonged overall survival; the estimated 
survival rate at 24 months was 98% with ibrutinib versus 85% with chlorambucil, 
with a relative risk of death that was 84% lower in the ibrutinib group than in the 
chlorambucil group (hazard ratio, 0.16; P = 0.001). The overall response rate was 
higher with ibrutinib than with chlorambucil (86% vs. 35%, P<0.001). The rates of 
sustained increases from baseline values in the hemoglobin and platelet levels were 
higher with ibrutinib. Adverse events of any grade that occurred in at least 20% of 
the patients receiving ibrutinib included diarrhea, fatigue, cough, and nausea; ad-
verse events occurring in at least 20% of those receiving chlorambucil included 
nausea, fatigue, neutropenia, anemia, and vomiting. In the ibrutinib group, four 
patients had a grade 3 hemorrhage and one had a grade 4 hemorrhage. A total of 
87% of the patients in the ibrutinib group are continuing to take ibrutinib.
CONCLUSIONS
Ibrutinib was superior to chlorambucil in previously untreated patients with CLL 
or small lymphocytic lymphoma, as assessed by progression-free survival, overall 
survival, response rate, and improvement in hematologic variables. (Funded by 
Pharmacyclics and others; RESONATE-2 ClinicalTrials.gov number, NCT01722487.)
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Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries; it affects 
primarily older persons, with a median age at 
diagnosis of 72 years.1,2 Chlorambucil has been 
a standard first-line therapy in CLL, especially for 
older patients or those with coexisting condi-
tions.1,3 Until recently, no treatment was clearly 
superior to chlorambucil in this population.3-7 
Fludarabine or bendamustine has been associated 
with higher response rates and longer progres-
sion-free survival than those with chlorambucil, 
but both have also been associated with higher 
rates of toxic effects, and neither has provided 
overall survival benefit.3,5,6,8 In previously un-
treated patients who were younger than 75 years 
of age, bendamustine was associated with longer 
progression-free survival as compared with chlo-
rambucil (median, 21.6 months vs. 8.3 months).5
Only recently have data from randomized 
studies shown improved outcomes with the ad-
dition of anti-CD20 monoclonal antibodies to 
chlorambucil.9,10 In the three-group randomized 
CLL11 study conducted by the German CLL 
Study Group, which involved previously untreat-
ed patients with coexisting conditions, the me-
dian progression-free survival was 29.9 months 
with the combination of obinutuzumab and 
chlorambucil, 16.3 months with the combination 
of rituximab and chlorambucil, and 11.1 months 
with chlorambucil alone; overall survival was 
longer with the combination regimens than with 
chlorambucil.11 In another phase 3 study, which 
involved previously untreated patients who were 
not considered to be candidates for fludarabine-
containing therapy, the median progression-free 
survival was 13.1 months with chlorambucil ver-
sus 22.4 months with the combination of chlo-
rambucil and ofatumumab.10
Chemoimmunotherapy with fludarabine, cyclo-
phosphamide, and rituximab is standard in 
younger patients with CLL,12 but because of 
treatment-related toxic effects, this regimen is not 
suitable for older patients or those with coexist-
ing conditions.13 Patients who are 65 years of age 
or older do not have the same efficacy benefit, 
and they have more toxic effects than do younger 
patients treated with this combination chemo-
immunotherapy.13-15 Moreover, although the me-
dian progression-free survival with first-line flu-
darabine, cyclophosphamide, and rituximab is 
approximately 52 months, patients with high-risk 
genetic abnormalities (chromosome 17p13.1 or 
11q22.3 deletion) or unmutated IGHV have infe-
rior outcomes, with approximately 35 to 50% of 
the patients having progressive disease within 
3 years.12
Ibrutinib is a first-in-class oral covalent in-
hibitor of Bruton’s tyrosine kinase (BTK) that 
has been approved for the treatment of patients 
with CLL who have received at least one prior 
therapy and as primary therapy for patients with 
CLL who have chromosome 17p13.1 deletion.16,17 
BTK is essential for signaling by means of the 
B-cell receptor and chemokine receptors, which 
CLL cells use for survival, proliferation, and tis-
sue homing.18-22 In pharmacodynamic studies of 
ibrutinib in vivo in patients with CLL, ibrutinib 
inhibited leukemia-cell proliferation and acceler-
ated CLL cell death.23-25
In the phase 3 Study of Ibrutinib versus Ofa-
tumumab in Patients with Relapsed or Refractory 
Chronic Lymphocytic Leukemia (RESONATE) in-
volving patients with previously treated CLL, 
single-agent ibrutinib showed superior efficacy 
to ofatumumab, with a risk of progression that 
was 78% lower and a risk of death that was 57% 
lower.26 In early-phase data from 31 previously 
untreated patients with CLL who were 65 years 
of age or older, the overall response rate with 
ibrutinib was 84% (with a complete response in 
23% of the patients); the estimated rate of pro-
gression-free survival at 30 months was 96%, 
and the overall survival rate was 97%, with 81% 
of the patients continuing to take daily ibrutinib 
after 3 years of follow-up.27
These findings suggest a role for single-agent 
ibrutinib as initial treatment in patients with 
CLL. We conducted a multicenter, open-label, 
randomized phase 3 trial (RESONATE-2; study 
number, PCYC-1115-CA) to evaluate the efficacy 
and safety of single-agent ibrutinib as compared 
with chlorambucil in patients 65 years of age or 
older with previously untreated CLL.
Me thods
Patients
Eligible patients were 65 years of age or older 
and had previously untreated CLL or small lym-
phocytic lymphoma requiring therapy.28 Other 
eligibility criteria included an Eastern Coopera-
tive Oncology Group (ECOG) performance-status 
score of 2 or less (on a scale from 0 to 5, with 
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0 indicating no symptoms and higher numbers 
indicating increasing disability), an absolute 
neutrophil count of 1000 cells or more per cubic 
millimeter, a platelet count of 50,000 or more 
per cubic millimeter, and adequate liver and 
kidney function. Patients were ineligible if they 
had chromosome 17p13.1 deletion. All the pa-
tients provided written informed consent.
Study Oversight and Conduct
The study was approved by the institutional re-
view board or independent ethics committee at 
each institution and was conducted in accor-
dance with the principles of the Declaration of 
Helsinki and the International Conference on 
Harmonisation Good Clinical Practice guide-
lines. The study was sponsored and designed by 
Pharmacyclics. All the investigators and their 
research teams collected the data. The sponsor 
confirmed the accuracy of the data and com-
piled the data for analysis. All the authors had 
full access to the data and were involved in the 
interpretation of the data.
The first draft of the manuscript was collab-
oratively written by the first and last authors and 
two authors who are employees of the sponsor. 
Editorial support was provided by a professional 
medical writer, with funding from the sponsor. 
All the authors contributed to the revisions and 
final approval of the manuscript and made the 
decision to submit the manuscript for publica-
tion. All the authors vouch for the accuracy and 
completeness of the reported data and analyses 
and confirm adherence of the trial to the proto-
col (available with the full text of this article at 
NEJM.org). An independent review committee 
whose members were unaware of the treatment 
assignments and lymphocyte counts evaluated 
response and progression.
Randomization and Treatment
Patients were enrolled in the United States, 
countries in Europe, and other countries (see the 
Supplementary Appendix, available at NEJM.org). 
Patients were randomly assigned, in a 1:1 ratio, 
to receive either oral ibrutinib (at a dose of 420 mg 
once daily) until disease progression or develop-
ment of an unacceptable level of toxic effects or 
up to 12 cycles of chlorambucil (at a dose of 
0.5 mg per kilogram of body weight on days 1 and 
15 of each 28-day cycle, which was increased to a 
maximum of 0.8 mg per kilogram, if there was 
not an unacceptable level of toxic effects) until 
disease progression, determination of a lack of 
efficacy (defined as a lack of complete or partial 
response, as determined by the investigator), or 
development of an unacceptable level of toxic 
effects.
Patients with disease progression that was 
confirmed by the independent review committee 
were enrolled in a separate extension study 
(PCYC-1116-CA) for follow-up and second-line 
treatment according to the investigator’s choice. 
Treatment in the PCYC-1116-CA study could in-
clude ibrutinib for chlorambucil-treated patients 
who had disease that progressed according to 
the independent review committee and who had 
an indication for treatment according to the In-
ternational Workshop on Chronic Lymphocytic 
Leukemia (iwCLL) criteria28 (Table S1 in the 
Supplementary Appendix) as determined by the 
investigator.
Study End Points
The primary end point was progression-free sur-
vival, as assessed by the independent review 
committee according to the iwCLL criteria,28 
with modification for treatment-related lympho-
cytosis such that isolated treatment-related lym-
phocytosis (in the absence of other clinical, 
computed tomographic, or laboratory evidence 
of disease progression) was not considered to 
indicate progressive disease.29 Key secondary end 
points included overall survival, overall response 
(details in Table S2 in the Supplementary Ap-
pendix), the rate of sustained improvement in 
hematologic variables, and safety. Sustained 
hematologic improvement was defined as an 
increase in hematologic variables that was sus-
tained continuously for at least 56 days without 
transfusion or growth factors, as measured by 
the following: an increase in the platelet count 
or absolute neutrophil count from baseline of at 
least 50%, or for hemoglobin, an increase from 
baseline of ≥2 g per deciliter; or for patients 
with baseline cytopenia, an increase to a hemo-
globin level of more than 11 g per deciliter, a 
platelet count of more than 100,000 per cubic 
millimeter, or an absolute neutrophil count of 
more than 1500 per cubic millimeter.
Safety assessments included evaluation of ad-
verse events and measurement of laboratory 
variables. The severity of nonhematologic adverse 
events was graded according to the Common 
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Terminology Criteria for Adverse Events, version 
4.03.30 Hematologic adverse events were graded 
according to the iwCLL criteria.28
Patients were monitored every 2 weeks during 
cycles 1 and 2, every 4 weeks during cycles 3 
through 12, and then every 8 weeks starting at 
cycle 13. The assessment of response was con-
ducted every 4 cycles until disease progression 
or until study closure.
Statistical Analysis
The study was powered on the basis of the pri-
mary end point, progression-free survival. We 
calculated that the occurrence of 81 events of 
death or disease progression would provide the 
study with approximately 85% power to detect a 
hazard ratio for progression or death of 0.50 
with ibrutinib as compared with chlorambucil, 
with the use of a one-sided log-rank test at an 
alpha level of 0.025. No interim analysis was 
planned. The type I error was controlled with 
the use of a hierarchical closed-testing procedure 
for the primary end point and ordered secondary 
end points including, in order, overall response 
rate, overall survival, and sustained hematologic 
improvement.
The primary analysis was a two-sided log-rank 
test stratified according to two randomization 
factors: ECOG performance-status score (0 or 1 
vs. 2) and disease stage (Rai stage ≤II vs. III or IV). 
The overall response rate was analyzed by means 
of the Cochran–Mantel–Haenszel chi-square test, 
stratified according to the two randomization 
factors. Overall survival was analyzed with the 
use of an unstratified log-rank test, owing to 
small event numbers. The rate of sustained 
hematologic improvement was compared by a 
chi-square test for treatment effect.
R esult s
Patients
Beginning in March 2013, a total of 269 patients 
underwent randomization (Fig. S1 in the Supple-
mentary Appendix). The characteristics of the 
patients at baseline were well balanced between 
the two groups (Table 1). The median age of the 
patients was 73 years, with 70% of the patients 
being 70 years of age or older; 45% of the pa-
tients had advanced-stage disease (Rai stage III or 
IV), and 20% had chromosome 11q22.3 deletion.
The median follow-up was 18.4 months, with 
87% of the patients who had been randomly as-
signed to ibrutinib still receiving treatment at 
the time of analysis. In the chlorambucil group, 
40% of the patients completed the maximum of 
12 cycles of treatment (mean dose per adminis-
tration, 0.6 mg per kilogram; range, 0.3 to 0.8).
Efficacy
Progression-free Survival
Ibrutinib resulted in significantly longer progres-
sion-free survival than that with chlorambucil 
(median, not reached vs. 18.9 months) as as-
sessed by the independent review committee, 
with a relative risk of progression or death that 
was 84% lower than that with chlorambucil 
(hazard ratio, 0.16; 95% confidence interval [CI], 
0.09 to 0.28; P<0.001) (Fig. 1A). The rate of 
progression-free survival at 18 months was 90% 
in the ibrutinib group versus 52% in the chlor-
ambucil group.
The results of the analysis of progression-free 
survival were consistent in the higher-risk sub-
groups, including patients with Rai stage III or 
IV disease, worse ECOG performance-status score, 
presence of chromosome 11q22.3 deletion, and 
unmutated IGHV status (Fig. 1C). The rate of 
progression-free survival at 18 months with 
ibrutinib was approximately 89% both in the 
subgroup with unmutated IGHV and in the sub-
group with mutated IGHV; the corresponding 
rates of progression-free survival with chloram-
bucil were 47% and 51%. Investigator-assessed 
progression-free survival, a key sensitivity analy-
sis, also showed significant prolongation of 
progression-free survival with ibrutinib (median, 
not reached vs. 15.0 months), with a relative risk 
of progression or death that was 91% lower than 
that with chlorambucil (hazard ratio, 0.09; 95% 
CI, 0.04 to 0.17; P<0.001) (Fig. 1B). The only case 
of Richter’s transformation (CLL that has evolved 
into an aggressive, rapidly growing large-cell 
lymphoma) occurred in the chlorambucil group.
Overall Survival
Ibrutinib significantly prolonged overall survival 
(median, not reached in either group). The over-
all survival rate at 24 months was 98% with 
ibrutinib versus 85% with chlorambucil, with a 
relative risk of death with ibrutinib that was 
84% lower than that with chlorambucil (hazard 
ratio, 0.16; 95% CI, 0.05 to 0.56; P = 0.001) 
(Fig. 2A).
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Over the median follow-up of 18.4 months, 
3 patients in the ibrutinib group died, as com-
pared with 17 in the chlorambucil group. The 
3 patients in the ibrutinib group who died in-
cluded 1 who died from a klebsiella infection 
and 2 who died from unknown causes (Table S3 
in the Supplementary Appendix). Among the 17 
patients in the chlorambucil group who died, 
the most common causes were progressive dis-
ease and infection. None of the patients in the 
ibrutinib group who had disease that progressed 
died during follow-up.
Response
The response rate as assessed by the indepen-
dent review committee was significantly higher 
Characteristic
Ibrutinib 
(N = 136)
Chlorambucil 
(N = 133)
Age
Median (range) — yr 73 (65–89) 72 (65–90)
≥70 yr — no. (%) 96 (71) 93 (70)
Male sex — no. (%) 88 (65) 81 (61)
ECOG performance-status score — no. (%)†
0 60 (44) 54 (41)
1 65 (48) 67 (50)
2 11 (8) 12 (9)
Diagnosis — no. (%)
Chronic lymphocytic leukemia 123 (90) 126 (95)
Small lymphocytic lymphoma 13 (10) 7 (5)
Rai stage III or IV — no. (%) 60 (44) 62 (47)
Bulky disease ≥5 cm — no. (%)‡ 54 (40) 40 (30)
Chromosome 11q22.3 deletion — no. (%) 29 (21) 25 (19)
Unmutated IGHV — no. (%) 58 (43) 60 (45)
Cytopenia at baseline — no. (%)
Any cytopenia 72 (53) 73 (55)
Hemoglobin ≤11 g/dl 51 (38) 55 (41)
Platelet count ≤100,000/mm3 35 (26) 28 (21)
Absolute neutrophil count ≤1500/mm3 10 (7) 7 (5)
Lactate dehydrogenase
Median (range) — U/liter 199 (52–1188) 195 (110–1347)
>250 U/liter — no. (%) 39 (29) 31 (23)
β2-Microglobulin
Median (range) — mg/liter 5 (2–20) 5 (1–39)
>3.5 mg/liter — no. (%) 85 (62) 89 (67)
Cumulative Illness Rating Scale score >6 — no. (%)§ 42 (31) 44 (33)
Creatinine clearance <60 ml/min — no. (%) 60 (44) 67 (50)
Median time from initial diagnosis (range) — mo 31 (1–241) 31 (1–294)
*  There were no significant between-group differences at baseline.
†  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symp-
toms and higher numbers indicating increasing disability.
‡  Measurement was based on the longest diameter of the largest lymph node at screening, according to assessment by 
an independent review committee.
§  Scores on the Cumulative Illness Rating Scale range from 0 to 52, with higher scores indicating worse health status.
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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No. at Risk
Ibrutinib
Chlorambucil
136
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133
121
123
69
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10
69
31
2
0
0
0
Ibrutinib
Ibrutinib
Ibrutinib
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Chlorambucil
Median (mo) 15.0 NR
0.03 1.0 2.0 4.0 10.0
All patients
Age
<70 yr
≥70 yr
Sex
Male
Female
Geographic region
United States
Other
Rai stage
≤II
III or IV
ECOG performance-status score
0 or 1
2
Bulky disease
<5 cm
≥5 cm
Lactate dehydrogenase
≤ULN
>ULN
Cytopenia
Yes
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 Chromosome 11q22.3 deletion 
Yes
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IGHV
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β2 Microglobulin
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>3.5 mg/liter
Hazard Ratio (95% CI)No. of PatientsSubgroup
0.001
269
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0.15 (0.07–0.34)
0.15 (0.08–0.28)
0.19 (0.04–0.98)
0.19 (0.09–0.39)
0.11 (0.04–0.27)
0.14 (0.07–0.28)
0.21 (0.08–0.54)
0.18 (0.09–0.37)
0.13 (0.05–0.33)
0.03 (0.00–0.23)
0.23 (0.13–0.43)
0.15 (0.05–0.43)
0.13 (0.06–0.31)
0.29 (0.09–0.92)
0.15 (0.08–0.29)
Ibrutinib
Better
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Better
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in the ibrutinib group than in the chlorambucil 
group (86% vs. 35%) (Fig. 2B); 4% of the patients 
in the ibrutinib group had a partial response 
with lymphocytosis. Details regarding the fre-
quency and duration of lymphocytosis with 
ibrutinib are provided in Table S4 in the Supple-
mentary Appendix. Complete responses (includ-
ing those in patients with incomplete blood-
count recovery) occurred in 4% of the patients in 
the ibrutinib group and in 2% of those in the 
chlorambucil group (Fig. 2B).
Hematologic Variables
The rates of sustained improvement in hemato-
logic variables were significantly higher with 
ibrutinib than with chlorambucil (Table S5 in 
Supplementary Appendix). Among patients with 
anemia at baseline, a significantly higher pro-
portion of patients in the ibrutinib group than 
in the chlorambucil group had sustained im-
provement in the hemoglobin level (84% vs. 
45%, P<0.001) (Table S6 in the Supplementary 
Appendix). Similarly, among patients who had 
thrombocytopenia at baseline, a significantly 
higher proportion of patients in the ibrutinib 
group than in the chlorambucil group had sus-
tained improvement in the platelet count (77% 
vs. 43%, P = 0.005). Changes in hematologic 
variables over time are shown in Figure 3.
Safety
The most common adverse events, defined as 
those that occurred in 15% or more of the pa-
tients in either treatment group, are shown in 
Table 2 and in Table S7 in the Supplementary 
Appendix. The median period of exposure to the 
study treatment was 17.4 months (range, 0.7 to 
24.7) in the ibrutinib group versus 7.1 months 
(range, 0.5 to 11.7) in the chlorambucil group, 
hence the corresponding collection period for 
adverse-event data was longer in the ibrutinib 
group. In the ibrutinib group, diarrhea was the 
most frequent adverse event (in 42% of the pa-
tients, including grade 3 diarrhea in 4%) (Table 
S7 in the Supplementary Appendix). Other ad-
verse events that occurred in 20% or more of the 
patients in the ibrutinib group were fatigue, 
nausea, and cough. In the chlorambucil group, 
nausea, fatigue, neutropenia, anemia, and vom-
iting were observed in 20% or more of the pa-
tients; all these events occurred at a higher fre-
quency in the chlorambucil group than in the 
ibrutinib group (Table S7 in the Supplementary 
Appendix).
Discontinuation of treatment owing to ad-
verse events occurred less frequently in the ibru-
tinib group than in the chlorambucil group (in 
9% vs. 23% of the patients). Adverse events of 
grade 3 or higher and serious adverse events are 
listed in Table 2. Hypertension was observed in 
14% of the patients in the ibrutinib group, with 
grade 3 hypertension occurring in 4% and no 
events of grade 4 or 5. All six patients with grade 
3 hypertension were treated with antihyperten-
sive medication and did not require a dose re-
duction or discontinuation of ibrutinib. Four of 
these patients had a history of hypertension; 
blood-pressure values over time in these patients 
are shown in Figure S2 in the Supplementary 
Appendix.
Atrial fibrillation occurred in eight patients 
(6%) in the ibrutinib group, which was of grade 
2 in six patients and grade 3 in two. Atrial fibril-
lation was managed with discontinuation of the 
study drug in two patients (1%) and without 
modification of the ibrutinib dose in the re-
maining six patients. Seven of these eight pa-
tients had a history of hypertension, coronary 
artery disease, or myocardial ischemia. One pa-
tient in the chlorambucil group had atrial fibril-
lation.
During a median of 17.4 months of exposure 
to ibrutinib, major hemorrhage (defined as any 
Figure 1 (facing page). Progression-free Survival  
with Ibrutinib versus Chlorambucil.
Shown is progression-free survival as assessed by the 
independent review committee (Panel A) and by the in-
vestigators (Panel B). The tick marks indicate patients 
with censored data. The median progression-free surviv-
al in the ibrutinib group was not reached (NR). Panel C 
shows subgroup analyses of progression-free survival 
as forest plots of hazard ratios for disease progression 
or death. The sizes of the circles are proportional to 
the sizes of the subgroups; error bars indicate 95% 
confidence intervals. The dashed vertical line repre-
sents the overall treatment effect for all patients. The 
upper limit of the normal range (ULN) for the lactate 
dehydrogenase level was 250 U per liter. Eastern Coop-
erative Oncology Group (ECOG) performance-status 
scores range from 0 to 5, with 0 indicating no symp-
toms and higher scores indicating increasing disability.
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serious or grade 3 or higher hemorrhage or cen-
tral nervous system hemorrhage of any grade) 
occurred in 4% of the patients in the ibrutinib 
group (six patients, with one having grade 2 
hemorrhage, four having grade 3, and one hav-
ing grade 4) (Table S8 in the Supplementary 
Appendix). Hemorrhage led to the discontinua-
tion of treatment in three of these patients; three 
of the six patients were receiving concomitant 
low-molecular-weight heparin, aspirin, or vita-
Overall Response Rate Ibrutinib Chlorambucil
% of patients
Rate Ratio (95% CI) P Value
With PR-L
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min E at the time of the event. Major hemor-
rhage in the central nervous system included one 
grade 4 intraparenchymal hemorrhage related to 
transformation of an ischemic stroke in a pa-
tient with diabetes and hypertension and one 
grade 3 post-traumatic subdural hematoma. Ma-
jor hemorrhage occurred in 2% of the patients 
in the chlorambucil group over the 7.1-month 
period of exposure.
Discussion
In this randomized study involving older pa-
tients with previously untreated CLL or small 
lymphocytic lymphoma, ibrutinib was superior 
to chlorambucil with respect to progression-free 
and overall survival, response rate, and improve-
ment in hematologic variables. The relative risk 
of progression was 84% lower and the relative 
risk of death was also 84% lower with ibrutinib 
than with chlorambucil. Ibrutinib toxicity was 
modest in the majority of patients, with 87% of 
the patients continuing to take the single-agent 
therapy at a median follow-up of 18.4 months.
All current standards for first-line CLL thera-
py are based on cytotoxic chemotherapy, includ-
ing alkylating agents, purine analogues, or 
combinations thereof, except for patients with 
chromosome 17p13.1 deletion, for whom ibruti-
nib is a primary consideration for first-line 
therapy according to consensus guidelines.16,17,31,32 
In addition to their myelosuppressive effects, 
these cytotoxic chemotherapy approaches may 
be associated with expansion of subclones with 
high-risk genetic abnormalities (e.g., TP53 or 
NOTCH1 mutation)33-35 and an increased risk of 
secondary cancers, including treatment-related 
myelodysplasia and acute myeloid leukemia.36,37
When this study was initiated, single-agent 
chlorambucil was considered to be a standard 
first-line treatment in older patients with 
CLL.1,31,38,39 Phase 3 studies have only recently 
shown improvement in outcomes when chlor-
ambucil is coadministered with anti-CD20 
monoclonal antibodies.9,10 Depending on the 
anti-CD20 agent used in these combinations, the 
median progression-free survival has been re-
ported as 16.3 months (with rituximab and 
chlorambucil),11 22.4 months (with ofatumumab 
and chlorambucil),10 and 29.9 months (with 
obinutuzumab and chlorambucil).11 The addition 
of an anti-CD20 agent that requires a slow infu-
sion has been associated with infusion reactions 
of grade 3 or higher (in 4 to 20% of patients) 
and with higher rates of neutropenia of grade 3 
or higher (in 27 to 35%) than have been ob-
served with chlorambucil alone.9,10
Similar to results observed in patients with 
relapsed disease, the finding of a positive effect 
of ibrutinib on progression-free survival in the 
current study was seen in high-risk subgroups, 
including patients with Rai stage III or IV dis-
ease, those with chromosome 11q22.3 deletion, 
and those with unmutated IGHV. At 18 months, 
the rate of progression-free survival with ibruti-
nib as assessed by the independent review com-
mittee was 90%, and the rate as assessed by the 
investigator was 94%; the median progression-
free survival with ibrutinib could not be esti-
mated owing to the small number of progres-
sion events. The median progression-free 
survival of 18.9 months with chlorambucil that 
was observed in this study appears to be gener-
ally longer than that reported in previous trials 
with chlorambucil in previously untreated pa-
tients, in which the median progression-free 
survival ranged from 8.3 to 20.0 months.3-5,8,10,11 
The relatively strong performance of chlorambu-
cil in the current study may have been influ-
enced, in part, by a generally longer exposure to 
Figure 2 (facing page). Overall Survival and Response 
Rates with Ibrutinib versus Chlorambucil.
Shown are overall survival with ibrutinib versus chloram-
bucil (Panel A) and the best response to treatment as 
assessed by the independent review committee (Panel B). 
The tick marks indicate patients with censored data. 
Categories for response assessments included com-
plete response (CR) or complete response with incom-
plete blood-count recovery (CRi), nodular partial re-
sponse (nPR; according to the International Workshop 
on Chronic Lymphocytic Leukemia criteria for response,28 
nPR was defined as a complete response with lymphoid 
nodules in the bone marrow), partial response (PR), 
partial response with lymphocytosis (PR-L), stable dis-
ease, and progressive disease. In the ibrutinib group, 
five patients (4%) had a complete response and one 
(1%) had a complete response with incomplete blood-
count recovery. In the chlorambucil group, two patients 
(2%) had a complete response. Data were unknown, 
missing, or could not be evaluated for six patients in 
the ibrutinib group and for eight in the chlorambucil 
group. The rate ratios and P values are based on the 
Cochran–Mantel–Haenszel chi-square test, stratified 
according to ECOG performance-status score (0 or 1 
vs. 2) and disease stage (Rai stage ≤II vs. III or IV). 
Percents may not sum as expected owing to rounding.
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chlorambucil than was used in earlier trials in-
volving previously untreated patients with CLL 
or by the exclusion of patients with chromosome 
17p13.1 deletion (typically 5 to 10% of previ-
ously untreated patients with CLL).
Ibrutinib substantially improved overall sur-
vival, with an overall survival rate of 98% at 24 
months, a finding that is consistent with the 
97% rate reported in a phase 2 study of ibrutinib 
with 3 years of follow-up.27 In these two studies, 
Figure 3. Hematologic Variables over Time in the Safety Population.
Shown are the mean hemoglobin values (Panel A) and mean platelet counts (Panel B) over time in the safety popu-
lation in each treatment group. The safety population included all patients who received at least one dose of the 
study drug. Each tick mark represents day 1 of the cycle (C). The baseline measurement was the last measurement 
on or before day 1 of the first cycle. I bars represent standard errors.
H
em
og
lo
bi
n 
(g
/d
l)
14
13
12
11
10
Visit
B Mean Platelet Count
A Mean Hemoglobin Level
No. of Patients
Ibrutinib
Chlorambucil
Ibrutinib
Ibrutinib
Chlorambucil
Chlorambucil
135
132
123
123
125
119
125
117
122
106
123
88
119
73
121
68
118
63
119
58
121
54
118
55
119
51
Ba
se
lin
e C2 C3 C4 C5 C6 C7 C8 C9 C1
0
C1
1
C1
2
C1
3
C2 C3 C4 C5 C6 C7 C8 C9 C1
0
C1
1
C1
2
C1
3
Pl
at
el
et
s 
pe
r 
m
m
3
200,000
180,000
160,000
140,000
120,000
100,000
Visit
No. of Patients
Ibrutinib
Chlorambucil
135
132
123
120
124
117
124
112
121
106
121
88
118
73
118
68
117
62
115
58
121
54
119
55
118
50
Ba
se
lin
e
The New England Journal of Medicine 
Downloaded from nejm.org on July 12, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med  373;25 nejm.org december 17, 2015 2435
Ibrutinib as Initial Ther apy in CLL
deaths (3 deaths among 136 patients and 1 
death among 31 patients, respectively) were lim-
ited to the early part of follow-up with a relative 
plateau in the survival curve thereafter. The 
magnitude of the difference in overall survival 
with ibrutinib as compared with chlorambucil 
(hazard ratio for death, 0.16) was greater than 
that observed in studies assessing the addition 
of anti-CD20 agents to chlorambucil (hazard 
ratio, 0.47 in one study11 and 0.91 in another 
study10). Given the availability of crossover for 
patients who had disease that progressed during 
chlorambucil treatment, the prolongation of 
overall survival, which was a major benefit in 
this study, suggests that patients have benefits 
with first-line ibrutinib treatment possibly ow-
ing to reduced CLL-related or treatment-related 
mortality before the initiation of second-line 
therapy. These findings suggest that better re-
sults with ibrutinib might be obtained when it is 
used as first-line treatment rather than for later 
relapses or in patients with refractory disease.
The response rate was significantly higher 
with ibrutinib than with chlorambucil (86% vs. 
35%). On the basis of results from an early-
phase study,27 the rate of complete response is 
likely to increase with continued ibrutinib ther-
apy. Furthermore, ibrutinib-treated patients had 
a restoration of bone marrow function, with a 
significantly higher rate of sustained improve-
ment in hematologic variables. This finding has 
particular clinical relevance because bone mar-
row failure is a common cause of complications 
in patients with CLL, with anemia and thrombo-
cytopenia being frequent indications for initiat-
ing treatment in this population.28
The safety of ibrutinib in this older popula-
tion of patients with CLL who often had clini-
cally significant coexisting conditions (Table 1) 
was consistent with that in previous reports. 
Exposure to treatment and adverse-event follow-
up was nearly 2.5 times as long with ibrutinib as 
with chlorambucil. Similar to findings in previ-
ous reports about ibrutinib, major hemorrhage 
was observed in 4% of the patients, with no fatal 
events, and atrial fibrillation occurred in 6%, 
with the majority of the events (in six of eight 
patients) being grade 2 events that were ob-
served over the period of 1.5 years while the 
patients were taking ibrutinib. Hypertension 
was reported more frequently with ibrutinib 
than with chlorambucil, with no events leading 
Variable
Ibrutinib 
(N = 135)
Chlorambucil 
(N = 132)
Duration of treatment — mo
Median 17.4 7.1
Range 0.7–24.7 0.5–11.7
Most common adverse event of any grade — 
no. of patients (%)*
Diarrhea 57 (42) 22 (17)
Fatigue 41 (30) 50 (38)
Cough 30 (22) 20 (15)
Nausea 30 (22) 52 (39)
Peripheral edema 25 (19) 12 (9)
Dry eye 23 (17) 6 (5)
Arthralgia 22 (16) 9 (7)
Neutropenia 21 (16) 30 (23)
Vomiting 18 (13) 27 (20)
Adverse event of grade ≥3 — no. of patients (%)†
Neutropenia 14 (10) 24 (18)
Anemia 8 (6) 11 (8)
Hypertension 6 (4) 0
Pneumonia 5 (4) 2 (2)
Diarrhea 5 (4) 0
Maculopapular rash 4 (3) 2 (2)
Decreased platelet count 4 (3) 1 (1)
Abdominal pain 4 (3) 1 (1)
Hyponatremia 4 (3) 0
Thrombocytopenia 3 (2) 8 (6)
Febrile neutropenia 3 (2) 3 (2)
Upper respiratory tract infection 3 (2) 2 (2)
Pleural effusion 3 (2) 1 (1)
Cellulitis 3 (2) 0
Fatigue 1 (1) 7 (5)
Syncope 1 (1) 3 (2)
Hemolytic anemia 0 3 (2)
Serious adverse event — no. of patients (%)†
Pneumonia 5 (4) 2 (2)
Basal-cell carcinoma 5 (4) 0
Hyponatremia 3 (2) 0
Pyrexia 1 (1) 5 (4)
*  The events listed are adverse events of any grade that occurred in at least 15% 
of patients in either treatment group and for which the frequency differed be-
tween treatment groups by at least 5%.
†  The events listed are adverse events of grade 3 or higher or serious adverse 
events that occurred in at least 2% of the patients in either treatment group. 
One death due to toxic hepatitis in the chlorambucil group was considered by 
the investigator to be possibly related to the study treatment; no other deaths 
were considered by the investigator to be related to the study treatment.
Table 2. Adverse Events and Duration of Treatment.
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to dose modification or having a severity of 
grade 4 or 5. The rates of fatigue, nausea, vomit-
ing, and myelosuppression were higher with 
chlorambucil than with ibrutinib. Early discon-
tinuation of treatment due to adverse events was 
more than twice as frequent with chlorambucil 
as with ibrutinib.
In conclusion, in this older population of 
patients with CLL, many of whom had coexist-
ing conditions, oral ibrutinib was administered 
continuously with a safety profile consistent 
with that in prior reports, which permitted the 
vast majority of patients to continue taking the 
treatment at the completion of the study. As 
compared with chlorambucil, a standard cyto-
toxic chemotherapy, ibrutinib was associated 
with significantly longer progression-free sur-
vival and overall survival and with higher rates 
of response and improvement in hematologic 
variables among patients with previously un-
treated CLL or small lymphocytic lymphoma.
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